Primary biliary cholangitis (PBC, formerly primary biliary cirrhosis) is a chronic cholestatic liver disease characterized by autoimmune destruction of small intrahepatic bile ducts. Anti-mitochondrial antibody (AMA) positivity is detected in 90-95% of cases and is pathognomonic for diagnosis. It shows marked predominance in middle-aged women (F:M = 9:1). The disease may progress from asymptomatic phase to pruritus, fatigue, and jaundice, ultimately to biliary cirrhosis and end-stage liver failure. Imaging findings include periportal halo sign, periportal lymphadenopathy, and cirrhosis findings in advanced stages. Ursodeoxycholic acid (UDCA) is first-line treatment providing biochemical response in 60% of patients.
Age Range
30-70
Peak Age
50
Gender
Female predominant
Prevalence
Uncommon
PBC pathogenesis is based on autoimmune destruction of small intrahepatic bile ducts (interlobular and septal ducts, diameter <100 um). T lymphocytes target bile duct epithelium (cholangiocytes) — specifically, autoimmune response develops against the E2 subunit of mitochondrial pyruvate dehydrogenase complex (AMA-M2 antigen). This autoimmune damage creates florid ductopenia (vanishing bile duct syndrome) — duct loss disrupts bile flow and initiates the cholestatic damage cascade. Accumulated bile acids create toxicity in hepatocytes and periductular fibrosis progresses. In imaging, small duct disease cannot be directly visualized — but periportal inflammation reflects as periportal halo on T2, chronic cholestasis as liver morphology changes (left lobe hypertrophy, caudate lobe enlargement), and advanced stages as cirrhosis findings. Periportal lymphadenopathy represents reactive inflammatory response.
Concentric hyperintense halo around portal triads on T2-weighted images — finding specific to PBC reflecting periportal inflammation and granulomatous ductitis. Periportal edema appearance without bile duct dilatation is characteristic for PBC and has value as a distinguishing sign from obstructive cholestasis.
Hyperintense halo in periportal areas on T2-weighted images — periportal inflammation and edema finding specific to PBC. Halo may create 'tram-track' appearance surrounding portal triad structures. In early-stage PBC, bile ducts may appear normal on imaging because affected ducts are too small (<100 um). Hepatic steatosis may accompany — visible as signal loss on T1 opposed-phase.
Report Sentence
Periportal hyperintense halo on T2-weighted series reflecting periportal inflammation pattern consistent with primary biliary cholangitis.
Reactive lymphadenopathy in hepatoduodenal ligament, portacaval area, and periportal regions on portal venous phase (short axis >1 cm). Lymph nodes show homogeneous enhancement without necrosis or conglomerate appearance — reactive character. Can be detected even in early PBC stages and correlates with clinical activity. Liver morphology may be normal or left lobe hypertrophy and caudate lobe enlargement may be noted.
Report Sentence
Reactive lymphadenopathy in hepatoduodenal ligament and periportal areas is noted, which may be associated with PBC in the clinical context.
PBC-specific liver morphology changes on T1-weighted images: left lobe (especially lateral segment) and caudate lobe hypertrophy with right lobe atrophy. These morphology changes begin before cirrhosis develops and are characteristic of cholestatic liver diseases. Liver signal may be normal or mildly decreased on T1. If iron deposition is present (transfusion or hemolysis-related), signal decrease on T1 and T2 is seen.
Report Sentence
Left lobe and caudate lobe hypertrophy with right lobe atrophy suggesting morphology change consistent with chronic cholestatic disease (PBC).
Increased echogenicity in periportal areas on US — reflecting periportal fibrosis and inflammation. In early stages, liver size is normal or hepatomegaly is present. In advanced stages, cirrhosis findings develop: nodular liver surface, splenomegaly, ascites. Bile duct dilatation is typically ABSENT — PBC is a small duct disease and large ducts remain normal. This feature is a differential from extrahepatic obstructive cholestasis.
Report Sentence
Increased periportal echogenicity without bile duct dilatation is noted; may be consistent with chronic cholestatic disease (PBC).
Diffuse signal increase in liver parenchyma on DWI with decreased ADC values — reflecting advanced fibrosis and inflammation. In early PBC stages, ADC values may be normal; ADC progressively decreases as fibrosis advances. If ADC map shows predominant periportal decrease, it reflects the periportal fibrosis pattern specific to PBC. If nodular regeneration develops (cirrhosis), nodules may show heterogeneous signal on DWI.
Report Sentence
Diffusion restriction and decreased ADC values in liver parenchyma are noted, consistent with advanced hepatic fibrosis.
No intrahepatic bile duct dilatation on non-contrast CT — PBC is a small duct disease and imaging-visible ducts (>2 mm) are normal. This finding combined with cholestatic biochemistry (elevated ALP, GGT) distinguishes PBC from obstructive cholestasis. Extrahepatic bile duct and gallbladder are also normal. Periportal hypodensity (edema/inflammation) may be seen. Hepatomegaly or left lobe/caudate lobe hypertrophy may accompany.
Report Sentence
No intrahepatic or extrahepatic bile duct dilatation is seen; suggests primary biliary cholangitis in conjunction with cholestatic biochemistry.
Criteria
Ductular inflammation and periportal hepatitis; limited fibrosis
Distinct Features
Imaging may be normal or mild periportal halo; liver morphology preserved
Criteria
Bridging fibrosis or cirrhosis; portal hypertension development
Distinct Features
Cirrhosis findings: nodular surface, splenomegaly, ascites, left lobe/caudate hypertrophy prominent
Criteria
Coexistence of PBC + autoimmune hepatitis features; meets Paris criteria
Distinct Features
More aggressive course, earlier cirrhosis development; combination immunosuppressive therapy required
Distinguishing Feature
PSC is a large duct disease showing multisegmental strictures + beaded appearance on MRCP; PBC is a small duct disease with normal large ducts
Distinguishing Feature
IgG4-SC shows large duct wall thickening and stricture + elevated serum IgG4 + steroid response; PBC has normal large ducts, AMA positive
Distinguishing Feature
Choledocholithiasis causes extrahepatic obstruction and duct dilatation; PBC has no duct dilatation
Distinguishing Feature
Benign biliary stricture shows localized narrowing and upstream dilatation; PBC shows no bile duct narrowing or dilatation
Urgency
routineManagement
medicalBiopsy
Not NeededFollow-up
6-monthPBC diagnosis can be made with AMA positivity + cholestatic biochemistry; biopsy is not always necessary. First-line treatment is UDCA (ursodeoxycholic acid, 13-15 mg/kg/day) providing biochemical response in 60% of patients. Obeticholic acid is second-line for UDCA non-responders. Liver transplantation may be needed in advanced stages. Imaging follow-up is performed for cirrhosis development, portal hypertension, and hepatocellular carcinoma (HCC) risk — HCC risk in PBC is higher than general population.
PBC is a chronic and progressive disease where early initiation of ursodeoxycholic acid (UDCA) treatment significantly improves prognosis. Liver transplantation may be required in advanced cases. AMA positivity (95%+) is diagnostic and imaging-based cirrhosis staging guides treatment planning.